Lead Product(s): Telitacicept
Therapeutic Area: Immunology
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Lilly Asia Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 02, 2020
Funds will support clinical trials and commercialization for its autoimmune, oncology and ophthalmology pipeline.